Navamedic sells chitin to Lytone Enterprise Inc. in Taiwan
21-Mar-2006
Chitin is the starting material for production of glucosamine, the active pharmaceutical ingredient in Navamedic's Glucomed product for osteoarthritis symptom treatment. Glucomed was recently approved for medicinal use in 20 European countries. Navamedic is currently building a network of marketing and distribution partners to prepare for a launch across Europe.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Last viewed contents
A(n academic) village to determine an enzyme's function
Go to page
STRATEC adjusts sales and earnings forecast for 2008
Go to page
List_of_crambid_genera:_X
Go to page
Syracuse University research team discovers switch that causes the body to produce cancerous cells
Go to page
Cells bulge to squeeze through barriers
Go to page
List_of_crambid_genera:_O
Go to page
New light shed on early stage Alzheimer's disease
Go to page
Vasopressin
Go to page
Nandrolone
Go to page
List_of_lymantriid_genera:J
Go to page
Acetazolamide
Go to page
List_of_lymantriid_genera:M
Go to page